Dashboard
Manage Tickers

PYPD PolyPid Ltd.

Nasdaq polypid.com


$ 3.33 $ -0.01 (-0.3 %)    

Thursday, 16-Oct-2025 15:26:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 599.45 $ -5.75 (-0.95 %)
DIA $ 459.39 $ -3.98 (-0.86 %)
SPY $ 660.45 $ -6.46 (-0.97 %)
TLT $ 91.36 $ 0.86 (0.95 %)
GLD $ 395.37 $ 4.19 (1.07 %)
$ 3.345
$ 3.37
$ 3.33 x 3
$ 3.35 x 100
$ 3.36 - $ 3.47
$ 2.30 - $ 3.93
62,271
na
nm
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

polypid-announces-that-dr-shmuel-sharoni-will-present-topline-phase-3-shield-ii-trial-results-for-d-plex-at-the-2025-american-college-of-surgeons-clinical-congress-in-chicago
PolyPid Announces That Dr. Shmuel Sharoni ...
09/30/2025 12:50:48

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgi...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
08/18/2025 12:08:41

cisco-to-rally-around-21-here-are-10-top-analyst-forecasts-for-thursday
Cisco To Rally Around 21%? Here Are 10 Top...
08/14/2025 18:01:31

craig-hallum-maintains-buy-on-polypid-lowers-price-target-to-13
Craig-Hallum Maintains Buy on PolyPid, Low...
08/14/2025 17:43:31

Craig-Hallum analyst Chase Knickerbocker maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $15 to ...

hc-wainwright--co-reiterates-buy-on-polypid-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Poly...
08/13/2025 17:40:49

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.

polypid-q2-eps-078-misses-055-estimate
PolyPid Q2 EPS $(0.78) Misses $(0.55) Esti...
08/13/2025 11:33:44

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.55) by ...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

reported-earlier-polypid-reveals-a-long-acting-glp-1-receptor-agonists-delivery-platform-targeting-the-diabetes-and-weight-loss-market-aims-to-subcutaneously-deliver-glp-1-for-approximately-60-days-compared-to-current-standard-of-care-of-weekly-injections
Reported Earlier: PolyPid Reveals A Long-A...
07/15/2025 18:43:03

PETACH TIKVA, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company")...

roth-capital-maintains-buy-on-polypid-lowers-price-target-to-9
Roth Capital Maintains Buy on PolyPid, Low...
06/18/2025 16:32:27

Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $12 t...

jmp-securities-maintains-market-outperform-on-polypid-lowers-price-target-to-14
JMP Securities Maintains Market Outperform...
06/17/2025 15:12:51

JMP Securities analyst Roy Buchanan maintains PolyPid (NASDAQ:PYPD) with a Market Outperform and lowers the price target fro...

reported-earlier-polypid-raises-267m-via-immediate-warrant-exercises-to-extend-runway-beyond-anticipated-fda-approval-of-d-plex
Reported Earlier, PolyPid Raises $26.7M Vi...
06/17/2025 06:39:34

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food ...

nano-cap-polypids-lead-drug-candidate-cuts-surgical-infection-risk-by-38-in-phase-3-trial
Nano-Cap PolyPid's Lead Drug Candidate Cut...
06/09/2025 16:53:14

PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal sur...

hc-wainwright--co-maintains-buy-on-polypid-raises-price-target-to-13
HC Wainwright & Co. Maintains Buy on PolyP...
06/09/2025 15:32:18

HC Wainwright & Co. analyst Brandon Folkes maintains PolyPid (NASDAQ:PYPD) with a Buy and raises the price target from $...

polypid-announces-results-from-shield-ii-phase-3-trial-of-d-plex100-for-preventing-ssis-in-abdominal-colorectal-surgery-patients-with-large-incisions
Polypid Announces Results From SHIELD II P...
06/09/2025 12:57:14

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial ...

why-circle-internet-group-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Circle Internet Group Shares Are Tradi...
06/09/2025 12:46:39

polypids-surgery-drug-cuts-infection-risk-by-38-in-major-phase-3-trial
PolyPid's Surgery Drug Cuts Infection Risk...
06/09/2025 11:33:40

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgi...

polypid-will-host-a-conference-call-and-webcast-to-report-topline-data-for-the-shield-ii-phase-3-trial-evaluating-d-plex100-for-the-prevention-of-surgical-site-infections-in-patients-undergoing-abdominal-colorectal-surgery-on-monday-june-9-at-830-am-et
PolyPid Will Host A Conference Call And We...
06/06/2025 20:06:58

PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surg...

this-excelerate-energy-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Excelerate Energy Analyst Begins Cove...
06/05/2025 19:17:32

roth-capital-initiates-coverage-on-polypid-with-buy-rating-announces-price-target-of-9
Roth Capital Initiates Coverage On PolyPid...
06/05/2025 17:47:31

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on PolyPid (NASDAQ:PYPD) with a Buy rating and announces Price...

hc-wainwright--co-assumes-polypid-at-buy-announces-price-target-of-11
HC Wainwright & Co. Assumes PolyPid at Buy...
06/02/2025 10:29:18

HC Wainwright & Co. analyst Brandon Folkes assumes PolyPid (NASDAQ:PYPD) with a Buy rating and announces Price Target of...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION